The latest market price and reference price of zolbetuximab in 2025

Zolbetuximab (zolbetuximab-clzb), as a new type of anti-tumor monoclonal antibody drug, has gradually gained attention in the domestic market in recent years. As of2025, the original drug of zotuximab has been officially launched in China. However, due to the short time to market, it has not yet been included in the medical insurance catalog, and the price information is not yet fully transparent. When purchasing, patients usually need to consult a hospital or regular pharmacy to obtain the latest and accurate drug prices.

In the international market, the original drug of zotuximab is available in European and Japanese versions, and the specifications are generally 100mg per box. The selling price in overseas markets is relatively stable, with a common price of about more than 7,000 yuan per box. However, the price will be affected by factors such as exchange rate fluctuations and sales channels, so there is a certain amount of room for fluctuation. Compared with China, because medical insurance has not yet covered it, the financial burden for patients to purchase medicines is relatively heavy.

At present, there are no generic drugs of zotuximab in the domestic market, which means that patients can only rely on the original drug for treatment. The lack of generic drugs limits the room for drug price reduction to a certain extent and also affects patient accessibility. In the future, with technological advancement and market competition, it is expected that more imitation versions will be launched on the market, which is expected to bring about price improvements.

Overall, as an emerging anti-cancer drug, zotuximab is relatively expensive and not covered by medical insurance. Patients should consult their doctors and pharmacies in detail before taking medication, and make reasonable medication choices based on their own financial situation and treatment needs. At the same time, paying attention to drug policy dynamics and market changes will help to obtain more favorable medication options.

Reference materials:https://www.astellas.com/en/news/29401